GovWire

Guidance: Sickle cell and thalassaemia (SCT) screening: programme overview

Public Health England

August 17
08:30 2023

Public information about SCT screening is available on the NHS website.

There are no risks associated with screening for SCT. It can however provide information that may mean families have to make further important decisions. It is an individuals choice whether or not to be screened.

The SCT screening handbook for antenatal laboratories and handbook for newborn laboratories set out interpretation and reporting guidelines related to laboratory processes, including which types of carrier states to report.

There is guidance on DNA testing for transfused babies which sets out the recommendations and processes for offering DNA tests to babies who have had a blood transfusion before newborn blood spot screening.

The screening inequalities strategy sets out the commitment to reduce inequalities and variation in screening participation to help make sure everyone has fair and equal access to services.

Patient confidentiality in population screening programmes explains how and why population screening programmes collect and process data.

Target population

Antenatal screening

Sickle cell disease (SCD) screening is offered to:

SCD screening is offered to all pregnant women in high prevalence areas. This is done using a simple blood test.

In low prevalence areas, the family origin questionnaire (FOQ) is used to determine if a person is likely to be a carrier for SCD or other haemoglobin disorder.

All pregnant women are offered screening for thalassaemia.

All biological fathers are offered screening if the pregnant woman is a genetic carrier for sickle cell disease or thalassaemia.

There are special circumstances where additional investigations may be required.

Newborn screening

All newborn babies are offered sickle cell screening as part of the newborn blood spot screening programme, usually when they are 5 days old.

Conditions screened for

The programme screens for:

Screening tests

The following screening tests may be offered:

Evidence base

SCT screening is one of 11 NHS national population screening programmes available in England.

The UK National Screening Committee (UK NSC) makes recommendations to ministers in the 4 UK countries on all aspects of population screening. It ensures that screening provides more benefit than harm, at a reasonable cost to the NHS.

Recommendations are based on internationally recognised criteria and a rigorous evidence review process.

There are separate UK NSC recommendations on:

Data and intelligence

See annual data collected from the linked antenatal and newborn SCT screening programme for data up to 31 March 2017.

For 1 April 2017 to 31 March 2021 data, see the joint antenatal screening standards data report.

For 1 April 2021 to 31 March 2022 data and onwards see our data collection page for Sickle cell and thalassaemia screening (SCT) standards reports

Key performance indicator (KPI) data reports are available for all 11 national screening programmes.

Requests for screening data and research

All requests for SCT screening data need to be approved by the antenatal and newborn (ANNB) screening research advisory committee (RAC).

See the

Related Articles

Comments

  1. We don't have any comments for this article yet. Why not join in and start a discussion.

Write a Comment

Your name:
Your email:
Comments:

Post my comment

Recent Comments

Follow Us on Twitter

Share This


Enjoyed this? Why not share it with others if you've found it useful by using one of the tools below: